Mauricio J. Reginato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mauricio J. Reginato has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Lorela Ciraku
Department of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania
16 shared publications - Alexej Dick
Department of Biochemistry & Molecular Biology Drexel University College of Medicine Philadelphia Pennsylvania USA
15 shared publications - Nicole L. Simone
Department of Radiation Oncology, Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
15 shared publications Lorela Ciraku
Department of Biochemistry and Molecular Biology, Drexel University College of Medicine
14 shared publications- Riley G. Young
Department of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania
14 shared publications - Wiktoria Gocal
Department of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania
14 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1973683
Killing with a purpose: harnessing immunological cell death in brain tumors
Primary and metastatic brain tumors remain among the most challenging malignancies to treat, with limited therapeutic options and poor clinical outcomes despite substantial advances in cancer immunotherapy. Although immune checkpoint blockade (ICB) and other immunotherapies have transformed the treatment landscape for many cancers, they have demonstrated only limited efficacy in brain tumors. This limited responsiveness reflects the unique immune landscape of the central nervous system (CNS), which restricts immune cell infiltration and is further shaped by a highly immunosuppressive tumor immune microenvironment (TIME) that suppresses effective antitumor immunity. Consequently, therapeutic strategies capable of enhancing tumor immunogenicity while overcoming local immune suppression are urgently needed. One promising approach is the induction of immunogenic cell death (ICD), a form of regulated cell death that stimulates anti-tumor immunity through the release of danger-associated molecular patterns (DAMPs), tumor antigens, and inflammatory cytokines and chemokines that promote immune activation. However, the ability of ICD to generate durable antitumor responses within brain tumors is therefore likely influenced by the complex immunosuppressive networks that characterize the brain TIME. In this review, we examine the major barriers to effective antitumor immunity within brain tumors, focusing on the immunosuppressive cellular and cytokine/chemokine molecular networks that shape the brain tumor immune microenvironment, the influence of tumor origin and subtype on immune composition, and the implications of these features for therapeutic responsiveness. We then discuss how ICD may help overcome these barriers by enhancing antigen presentation, immune cell recruitment, and adaptive immune priming. We review the principal ICD-associated cell death modalities, including ferroptosis, necroptosis, and pyroptosis, and summarize current therapeutic approaches capable of inducing these pathways in brain tumors, including radiotherapy, chemotherapy, targeted therapies, oncolytic viruses, and emerging nanomedicine-based strategies. Finally, we highlight clinical and preclinical evidence supporting ICD-relevant therapeutic approaches across glioblastoma (GBM) and brain metastases and discuss rational combination strategies may improve immune responsiveness and therapeutic outcomes in patients.
- 6 November 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1973683
Open AccessKilling with a purpose: harnessing immunological cell death in brain tumors
Primary and metastatic brain tumors remain among the most challenging malignancies to treat, with limited therapeutic options and poor clinical outcomes despite substantial advances in cancer immunotherapy. Although immune checkpoint blockade (ICB) and other immunotherapies have transformed the treatment landscape for many cancers, they have demonstrated only limited efficacy in brain tumors. This limited responsiveness reflects the unique immune landscape of the central nervous system (CNS), which restricts immune cell infiltration and is further shaped by a highly immunosuppressive tumor immune microenvironment (TIME) that suppresses effective antitumor immunity. Consequently, therapeutic strategies capable of enhancing tumor immunogenicity while overcoming local immune suppression are urgently needed. One promising approach is the induction of immunogenic cell death (ICD), a form of regulated cell death that stimulates anti-tumor immunity through the release of danger-associated molecular patterns (DAMPs), tumor antigens, and inflammatory cytokines and chemokines that promote immune activation. However, the ability of ICD to generate durable antitumor responses within brain tumors is therefore likely influenced by the complex immunosuppressive networks that characterize the brain TIME. In this review, we examine the major barriers to effective antitumor immunity within brain tumors, focusing on the immunosuppressive cellular and cytokine/chemokine molecular networks that shape the brain tumor immune microenvironment, the influence of tumor origin and subtype on immune composition, and the implications of these features for therapeutic responsiveness. We then discuss how ICD may help overcome these barriers by enhancing antigen presentation, immune cell recruitment, and adaptive immune priming. We review the principal ICD-associated cell death modalities, including ferroptosis, necroptosis, and pyroptosis, and summarize current therapeutic approaches capable of inducing these pathways in brain tumors, including radiotherapy, chemotherapy, targeted therapies, oncolytic viruses, and emerging nanomedicine-based strategies. Finally, we highlight clinical and preclinical evidence supporting ICD-relevant therapeutic approaches across glioblastoma (GBM) and brain metastases and discuss rational combination strategies may improve immune responsiveness and therapeutic outcomes in patients.
- 19 August 2026
- Published by Drexel University Libraries
The role of SLC7A11 in regulating breast cancer brain metastasis
Brain metastasis in breast cancer patients represents an advanced and often fatal stage of disease, with survival typically less than one year following diagnosis. Despite therapeutic progress in primary tumors, effective treatments for breast cancer brain metastasis (BCBM) remain limited, highlighting the need for new mechanistic insights and therapeutic strategies. Our lab has recently found that SLC7A11 levels are significantly enriched in BCBM patient samples and are required for BCBM growth in vivo. SLC7A11, is a cystine/glutamate antiporter and is critical for glutathione (GSH) synthesis and protection against ferroptosis, a form of iron-dependent cell death. While it's function in ferroptosis resistance is well established, it's broader role in BCBM progression remains incompletely defined. Proteomic analyses of breast cancer cells overexpressing SLC7A11 revealed upregulation of extracellular matrix (ECM) and integrin-associated proteins, prompting investigation into regulation of ECM signaling pathways. In this study, we demonstrate that SLC7A11 overexpression significantly increases integrin [alpha]3, [alpha]6, and [beta]1 protein levels and focal adhesion kinase (FAK) activity, as evidenced by increased phosphorylation at tyrosine 397. Consistent with this data, using clonogenic survival assays, SLC7A11 overexpressing breast cancer cells showed resistance to FAK inhibitor induced cell death. In order to evaluate therapeutic potential of FAK inhibitors, we utilized an ex vivo brain slice model of BCBM. Treatment with clinically relevant FAK inhibitors including, PND-1186 and Defactinib resulted in significant tumor regression compared to controls. These findings indicate that FAK signaling contributes to BCBM tumor maintenance and that it's inhibition can effectively suppress tumor growth. Collectively, our results identify SLC7A11 as a non-canonical regulator of ECM/integrin-mediated FAK survival signaling in brain metastatic breast cancer cells. Targeting this axis may represent a promising strategy to enhance therapeutic vulnerability and improve outcomes in patients with breast cancer brain metastasis.
- 19 August 2026
- Published by Drexel University Libraries
The role of SLC7A11 in regulating breast cancer brain metastasis
Brain metastasis in breast cancer patients represents an advanced and often fatal stage of disease, with survival typically less than one year following diagnosis. Despite therapeutic progress in primary tumors, effective treatments for breast cancer brain metastasis (BCBM) remain limited, highlighting the need for new mechanistic insights and therapeutic strategies. Our lab has recently found that SLC7A11 levels are significantly enriched in BCBM patient samples and are required for BCBM growth in vivo. SLC7A11, is a cystine/glutamate antiporter and is critical for glutathione (GSH) synthesis and protection against ferroptosis, a form of iron-dependent cell death. While it's function in ferroptosis resistance is well established, it's broader role in BCBM progression remains incompletely defined. Proteomic analyses of breast cancer cells overexpressing SLC7A11 revealed upregulation of extracellular matrix (ECM) and integrin-associated proteins, prompting investigation into regulation of ECM signaling pathways. In this study, we demonstrate that SLC7A11 overexpression significantly increases integrin [alpha]3, [alpha]6, and [beta]1 protein levels and focal adhesion kinase (FAK) activity, as evidenced by increased phosphorylation at tyrosine 397. Consistent with this data, using clonogenic survival assays, SLC7A11 overexpressing breast cancer cells showed resistance to FAK inhibitor induced cell death. In order to evaluate therapeutic potential of FAK inhibitors, we utilized an ex vivo brain slice model of BCBM. Treatment with clinically relevant FAK inhibitors including, PND-1186 and Defactinib resulted in significant tumor regression compared to controls. These findings indicate that FAK signaling contributes to BCBM tumor maintenance and that it's inhibition can effectively suppress tumor growth. Collectively, our results identify SLC7A11 as a non-canonical regulator of ECM/integrin-mediated FAK survival signaling in brain metastatic breast cancer cells. Targeting this axis may represent a promising strategy to enhance therapeutic vulnerability and improve outcomes in patients with breast cancer brain metastasis.
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
ACSS2 inhibitor induces cell death and lipid peroxidation in BCBM cells and is blocked by ferrostatin treatment.
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
ACSS2 inhibitor induces cell death and lipid peroxidation in BCBM cells and is blocked by ferrostatin treatment.
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
ACSS2-S267D mutant increases growth in the brain but not mammary fad pad and can partly rescue effects of CDK5 knockdown in BCBM cells.
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
ACSS2-S267D mutant increases growth in the brain but not mammary fad pad and can partly rescue effects of CDK5 knockdown in BCBM cells.
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
Genetic targeting of ACSS2 induces cell death and lipid peroxidation in BCBM cells and is blocked by ferrostatin treatment.
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
Genetic targeting of ACSS2 induces cell death and lipid peroxidation in BCBM cells and is blocked by ferrostatin treatment.
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
RNA-seq data of RNAi ACSS2 in BCBM cells.
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
RNA-seq data of RNAi ACSS2 in BCBM cells.
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
E2F1 overexpression can protect from erastin and ACSS2 inhibitor mediated ferroptosis and E2F1 levels are elevated in BCBM cells compared to parentals.
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
E2F1 overexpression can protect from erastin and ACSS2 inhibitor mediated ferroptosis and E2F1 levels are elevated in BCBM cells compared to parentals.
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
Quantification of western blots from Figure 1B.
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
Quantification of western blots from Figure 1B.
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
E2F1 binds SLC7A11 promoter and OGT-CDK5-ACSS2 pathway regulates E2F1 and SLC7A11 levels in breast cancer cells.
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
E2F1 binds SLC7A11 promoter and OGT-CDK5-ACSS2 pathway regulates E2F1 and SLC7A11 levels in breast cancer cells.
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
ACSS2 inhibitor shrinks preformed tumor and is blocked by ferrostatin treatment in BCBM cells ex vivo.
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
ACSS2 inhibitor shrinks preformed tumor and is blocked by ferrostatin treatment in BCBM cells ex vivo.